Celanese Corporation
NYSE:CEChemicals
-$0.24 today
- Market cap
- $5.29B
- Beta
- 0.74
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$9.98
- Dividend yield
- 0.24%
Volume 1.38M
Average 2.09M
CE Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Celanese CorporationNYSE: CE
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 16.3% from a year ago
Cash & equivalents stood at $1.36B at the end of Q2 FY2026, up 16.3% from a year earlier and down 22.4% from the prior quarter. Over 3 fiscal years it compounded at -5.7% a year.
Context
- Cash & equivalents amounted to 6.4% of total assets at the end of Q2 FY2026, up 1.4 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +16.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 1.26B USD
- Year-over-year change
- +31.3%
- 4-year CAGR
- +23.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.26B | +31.3% |
| FY2024 | 2024-12-31 | 962M | -46.7% |
| FY2023 | 2023-12-31 | 1.81B | +19.7% |
| FY2022 | 2022-12-31 | 1.51B | +181.3% |
| FY2021 | 2021-12-31 | 536M | — |
Cash & Equivalents vs competitors
How CE compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +16.3% is the 4th highest of 11, against a peer median of +3.2%.
- Cash & equivalents amounts to 6.4% of total assets for CE, versus a peer median of 8.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | ZAR 42.96B ZAR | +4.6% | -7.3% | 11.9% | |
| Jun 2026 | $1.36B USD | +16.3% | -5.7% | 6.4% | |
| Jun 2026 | $440M USD | +112.6% | -30.7% | 9.6% | |
| Mar 2026 | $428.75M USD | +132.7% | +63.4% | 20.3% | |
| Jun 2026 | $250M USD | +4.6% | +7.8% | 6.3% | |
| Mar 2026 | $119.68M USD | +5001.5% | +35.9% | 64.7% | |
| Aug 2026 | $97.23M USD | -20.6% | +10.3% | 1.8% | |
| Sep 2026 | $66.26M USD | +1.8% | +3.9% | 3.9% | |
| Jun 2026 | $31.02M USD | -45.3% | +20.4% | 1.3% | |
| Sep 2026 | $7.1M USD | -31.8% | -19.7% | 0.7% | |
| Jun 2026 | $1.78M USD | -99.6% | -6.6% | 41.7% | |
| Peer median (excluding CE) | — | +3.2% | +5.8% | 8.0% | |
Competitors are the stored peer set for CE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 536M | 1.51B | 1.81B | 962M | 1.26B |
| Short-term Investments | 10M | 0 | 0 | 0 | 0 |
| Net Receivables | 1.67B | 2.05B | 1.78B | 1.61B | 1.47B |
| Inventory | 1.52B | 2.81B | 2.36B | 2.28B | 2.22B |
| Other Current Assets | 70M | 241M | 272M | 285M | 743M |
| Total Current Assets | 3.81B | 6.61B | 6.22B | 5.15B | 5.69B |
| Property, Plant & Equipment (Net) | 4.43B | 6B | 6.01B | 5.66B | 5.44B |
| Goodwill | 1.41B | 7.14B | 6.98B | 5.39B | 4.17B |
| Intangible Assets | 735M | 4.11B | 3.98B | 3.64B | 3.18B |
| Long-term Investments | 823M | 1.06B | 1.22B | 1.22B | 1.25B |
| Tax Assets | 248M | 808M | 1.68B | 1.25B | 1.36B |
| Other Non-current Assets | 521M | 547M | 524M | 555M | 601M |
| Total Non-current Assets | 8.17B | 19.66B | 20.38B | 17.71B | 16B |
| Total Assets | 11.98B | 26.27B | 26.6B | 22.86B | 21.7B |
| Account Payables | 1.16B | 1.52B | 1.51B | 1.23B | 1.28B |
| Short-term Debt | 791M | 1.31B | 1.38B | 1.5B | 1.2B |
| Tax Payables | 81M | 151M | 153M | 4M | 189M |
| Deferred Revenue | 248M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 108M | 594M | 516M | 390M | 596M |
| Total Current Liabilities | 2.51B | 4.07B | 4.07B | 3.85B | 3.68B |
| Long-term Debt | 3.03B | 13.37B | 12.3B | 11.08B | 11.39B |
| Deferred Tax Liabilities | 555M | 1.24B | 999M | 933M | 512M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1B | 1.12B | 1.35B | 1.09B | 1.37B |
| Total Non-current Liabilities | 4.93B | 16.1B | 14.97B | 13.4B | 13.54B |
| Total Liabilities | 7.44B | 20.17B | 19.05B | 17.25B | 17.22B |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | 9.68B | 11.27B | 12.93B | 11.1B | 9.88B |
| Accumulated OCI | (329M) | (518M) | (744M) | (848M) | (776M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 348M | 468M | 461M | 434M | 423M |
| Total Equity | 4.54B | 6.11B | 7.55B | 5.61B | 4.47B |
| Total Debt | 4.2B | 15.13B | 14.1B | 12.95B | 12.93B |
| Net Debt | 3.67B | 13.62B | 12.29B | 11.99B | 11.67B |
Celanese Corporation
NYSE:CE
Intrinsic Alpha fair value
Locked
Current Price
$48.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.